2.280USD-35.77%Mkt Cap: 130.65M USDP/E: —Last update: 2026-05-22
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is s…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap130.65M USD
Enterprise Value103.05M USD
Revenue (TTM)0 USD
Gross Profit0 USD
Net Income (TTM)22.37M USD
Revenue/Share0.0000 USD
Last Price2.280 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees21
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.26
PEG—
EV/EBITDA-2.26
EV/Revenue—
P/SInfinity
P/B1.95
EPS (TTM)-0.77
EPS (Forward)-1.09
52W Range
1.93012% of range4.940
52W High4.940 USD
52W Low1.930 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin31.95%
ROE19.93%
ROA15.64%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF29.61M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-19.82%
Net Debt-100.38M USD
Net Debt/EBITDA2.20
Balance Sheet
Debt/Equity0.17
Current Ratio8.46
Quick Ratio8.14
Book Value/Sh1.820 USD
Cash/Share2.064 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.4 (Strong Buy)
Target (Mean)9.857 USD
Target Range7.000 USD – 14.00 USD
# Analysts7
Ownership
Shares Out.57.30M
Float46.26M
Insiders0.62%
Institutions78.66%
Short Interest
Short Ratio5.5d
Short % Float11.24%
Short % Out.7.81%
Shares Short4.48M
Short (prev mo.)5.07M
Technical
SMA 502.631 (-13.4%)
SMA 2002.947 (-22.6%)
Beta3.35
S&P 52W Chg28.31%
Avg Vol (30d)1.56M
Avg Vol (10d)2.10M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—